Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) was the target of a significant drop in short interest in December. As of December 30th, there was short interest totalling 592,200 shares, a drop of 17.4% from the December 15th total of 717,000 shares. Based on an average daily volume of 133,700 shares, the short-interest ratio is presently 4.4 days.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Annandale Capital LLC purchased a new stake in shares of Cue Biopharma in the 3rd quarter worth about $145,000. Sigma Planning Corp grew its position in shares of Cue Biopharma by 12.8% in the 3rd quarter. Sigma Planning Corp now owns 188,424 shares of the company's stock worth $420,000 after buying an additional 21,318 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Cue Biopharma in the 3rd quarter worth about $73,000. Voss Capital LLC grew its position in shares of Cue Biopharma by 100.0% in the 3rd quarter. Voss Capital LLC now owns 200,000 shares of the company's stock worth $446,000 after buying an additional 100,000 shares during the period. Finally, P.A.W. Capital Corp grew its position in shares of Cue Biopharma by 14.3% in the 3rd quarter. P.A.W. Capital Corp now owns 200,000 shares of the company's stock worth $446,000 after buying an additional 25,000 shares during the period. 31.87% of the stock is owned by hedge funds and other institutional investors.
Get
Cue Biopharma alerts:
Cue Biopharma Price Performance
NASDAQ:CUE traded up $0.11 during mid-day trading on Friday, hitting $3.49. 48,612 shares of the stock traded hands, compared to its average volume of 94,893. The business's 50-day moving average price is $3.16 and its 200 day moving average price is $2.98. Cue Biopharma has a 12-month low of $2.18 and a 12-month high of $11.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.04 and a quick ratio of 6.04.
Cue Biopharma (NASDAQ:CUE – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.07. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.65 million. Cue Biopharma had a negative net
margin of 500.66% and a negative return on equity of 77.78%. Research analysts predict that Cue Biopharma will post -1.43 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler began coverage on shares of Cue Biopharma in a research report on Sunday, November 20th. They set an "overweight" rating and a $7.00 price objective for the company.
Cue Biopharma Company Profile
(Get Rating)
Cue Biopharma, Inc is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease.
See Also
- Get a free copy of the StockNews.com research report on Cue Biopharma (CUE)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
